Quantum Genomics Société Anonyme announces that efficacy results for firibastat in its phase III study FRESH, are non-significant versus placebo. These results will be presented in detail at the AHA congress.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1276 EUR | +6.51% | +14.13% | +20.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.38% | 4.47M | |
+1.77% | 42.86B | |
+46.96% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- ALQGC Stock
- News Quantum Genomics
- Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments